DEA Proposes Schedule III: The Most Important US Cannabis Decision in 50 Years

53 Years of Schedule I — And Why It’s Finally Changing

Published August 30, 2023 — By Ann Karim, Senior Cannabis Editor

What HHS Recommended and Why the DEA Listened

In August 2023, the Department of Health and Human Services formally recommended to the Drug Enforcement Administration that cannabis be reclassified from Schedule I to Schedule III under the Controlled Substances Act. The recommendation followed a directive from President Biden ordering a review of cannabis scheduling — a review that took nearly two years. HHS based its conclusion on a comprehensive analysis of medical evidence, finding that cannabis has accepted medical uses (contradicting the core Schedule I criterion) and a lower potential for abuse than Schedule I and II substances. The DEA, while not bound by HHS recommendations, is required to take them seriously as part of its own rulemaking process. For cannabis businesses operating in legal US states, the news was electrifying. Cannabis stocks surged by as much as 20% in a single trading session. Reform advocates called it the most significant federal cannabis development since the Nixon administration placed cannabis in Schedule I in 1970, explicitly over the objection of the Shafer Commission, which had recommended decriminalization. The announcement came just months after Germany’s Bundestag voted to legalize cannabis, creating a sense of global momentum.

“For the first time in over 50 years, the federal government is acknowledging what science and millions of patients already know.” — Cannabis Industry Association statement, August 2023

The 280E Problem: How Scheduling Crushes Cannabis Businesses

Perhaps the most tangible impact of rescheduling would be relief from IRS Section 280E, a Reagan-era provision that prohibits businesses “trafficking” in Schedule I or II substances from deducting normal business expenses. For cannabis companies, this means paying income tax on gross revenue rather than profit — a crippling distortion that results in effective tax rates of 70% or higher for many operators. A dispensary paying $1M in rent, salaries, and utilities cannot deduct any of it if it sells cannabis. This structural penalty has driven dozens of legitimate licensed dispensaries into insolvency even as their businesses grew. Schedule III would move cannabis out of 280E’s reach, allowing standard business deductions and dramatically improving the financial viability of the legal industry. Analysts estimated that 280E relief alone would add billions of dollars back into the legal cannabis sector annually, accelerating the displacement of black-market supply. For patients relying on medical cannabis, the practical effect would be lower prices as operators’ cost structures normalize toward those of other retail businesses.

Banking, Research, and What Schedule III Still Won’t Fix

Beyond taxes, rescheduling would ease the banking crisis that has plagued the cannabis industry. Most federally chartered banks refuse to serve cannabis businesses out of fear of money-laundering liability, forcing operators to run dangerous cash-heavy businesses. While Schedule III alone does not resolve federal banking law conflicts, it removes a key argument used by risk-averse banks and creates political momentum for passage of the SAFE Banking Act. On the research side, Schedule I status has made clinical trials on cannabis extraordinarily difficult — requiring DEA-registered facilities and NIDA-approved supply that most researchers cannot access. Schedule III would lower these barriers, potentially unlocking advances in understanding cannabis’s therapeutic potential. However, rescheduling would not legalize cannabis federally, not enable interstate commerce, and not force prohibition states to change course. Check our global cannabis laws database and US cannabis guide for current status by state.

What This Means for the Future of US Cannabis Policy

The DEA’s proposed rulemaking process involves public comment periods and legal challenges that can take months or years to resolve. Nevertheless, the direction of travel is unmistakable. For the first time since Richard Nixon weaponized the Controlled Substances Act in 1970, the federal government is moving — however cautiously — toward acknowledging cannabis’s legitimate place in American medicine and culture. States like Ohio and Florida had active legalization debates running in parallel, and the federal signal emboldened state-level reformers. Internationally, observers in countries like Australia and Canada noted that US rescheduling would remove a major barrier to their own regulatory ambitions. The 53-year experiment with treating cannabis like heroin was, at last, approaching its end. And for those navigating workplace concerns, our drug test calculator remains an essential tool regardless of how federal law evolves.